A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Researchers assessed the efficacy of aflibercept 8 mg vs conventional 2 mg doses at 96 weeks in patients with diabetic ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...